$BLNC
Balance Labs, Inc.

2024 Q3 Form 10-Q Financial Statement

#000149315224031278 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $57.87K
YoY Change 40.56%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $83.69K $57.87K
YoY Change 142.72% 40.57%
Operating Profit -$83.69K -$57.87K
YoY Change 142.72% 40.57%
Interest Expense -$42.83K
YoY Change -175.26%
% of Operating Profit
Other Income/Expense, Net -$109.1K -$42.83K
YoY Change 218.63% -22.95%
Pretax Income -$100.7K
YoY Change 4.08%
Income Tax
% Of Pretax Income
Net Earnings -$192.8K -$100.7K
YoY Change 180.55% 4.08%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 21.67M shares 21.67M shares
Diluted Shares Outstanding 21.67M shares 21.67M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.3K $171.5K
YoY Change -65.98% -49.25%
Cash & Equivalents $30.41K $43.79K
Short-Term Investments $79.94K $127.7K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $110.3K $171.5K
YoY Change -65.98% -49.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $110.3K $171.5K
Total Long-Term Assets $0.00 $0.00
Total Assets $110.3K $171.5K
YoY Change -65.98% -49.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.953M
YoY Change 33.11%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.699M
YoY Change 0.0%
Long-Term Debt Due $280.0K
YoY Change 0.0%
Total Short-Term Liabilities $5.064M $4.932M
YoY Change 19.15% 17.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.064M $4.932M
Total Long-Term Liabilities $0.00
Total Liabilities $5.064M $4.932M
YoY Change 6.87% 5.31%
SHAREHOLDERS EQUITY
Retained Earnings -$5.766M -$5.573M
YoY Change 10.32% 8.05%
Common Stock $2.167K $2.167K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.953M -$4.761M
YoY Change
Total Liabilities & Shareholders Equity $110.3K $171.5K
YoY Change -65.98% -49.25%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$192.8K -$100.7K
YoY Change 180.55% 4.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$69.02K
YoY Change 78.52%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$69.02K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$69.02K
YoY Change 78.52%
FREE CASH FLOW
Cash From Operating Activities -$69.02K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4932002 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4763604 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4932002 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4763604 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5572741 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5355098 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4760526 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
171476 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220721 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4542883 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3181 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7725 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7222 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11531 usd
CY2024Q2 us-gaap Professional Fees
ProfessionalFees
8545 usd
CY2023Q2 us-gaap Professional Fees
ProfessionalFees
20193 usd
us-gaap Professional Fees
ProfessionalFees
24545 usd
us-gaap Professional Fees
ProfessionalFees
38975 usd
CY2024Q2 us-gaap Salaries And Wages
SalariesAndWages
46145 usd
CY2023Q2 us-gaap Salaries And Wages
SalariesAndWages
13252 usd
us-gaap Salaries And Wages
SalariesAndWages
91822 usd
us-gaap Salaries And Wages
SalariesAndWages
26941 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
57871 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
41170 usd
us-gaap Operating Expenses
OperatingExpenses
123589 usd
us-gaap Operating Expenses
OperatingExpenses
77447 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-57871 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-41170 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-123589 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-77447 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
14083 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1329 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
19770 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6644 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
56912 usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
56912 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
113824 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
113230 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42829 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-55583 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-94054 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-106586 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-100700 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-96753 usd
us-gaap Net Income Loss
NetIncomeLoss
-217643 usd
us-gaap Net Income Loss
NetIncomeLoss
-184033 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4659827 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-100700 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4760526 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4542883 usd
us-gaap Net Income Loss
NetIncomeLoss
-217643 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4760526 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4284592 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-96753 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4345345 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
us-gaap Net Income Loss
NetIncomeLoss
-184033 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4345345 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4345345 usd
us-gaap Net Income Loss
NetIncomeLoss
-217643 usd
us-gaap Net Income Loss
NetIncomeLoss
-184033 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5669 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5670 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
19770 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
6644 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-45000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
162729 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
87096 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69015 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52911 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69015 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52911 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112809 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
235311 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43794 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
182400 usd
CY2024Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69015 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43794 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5572741 usd
CY2024Q2 BLNC Working Capital Deficit
WorkingCapitalDeficit
-4760526 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zpXX4O3N4Qq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_867_zBYRNlBJAJdd">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q2 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
66432 shares
CY2024Q2 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
127682 usd
CY2024Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.92
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
19770 usd
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 share for 8 share reverse stock split
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zJprCe6ZJCx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zZ2kqieOytka">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of June 30, 2024, and December 31, 2023, the carrying value of marketable securities was $<span id="xdx_90F_eus-gaap--MarketableSecurities_iI_c20240630_zWBE4rRQHSU6" title="Marketable securities">127,682</span> and $<span id="xdx_908_eus-gaap--MarketableSecurities_iI_c20231231_zJNTHW0DfLLi" title="Marketable securities">107,912</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
127682 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
107912 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2575 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2394 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 BLNC Notes Receivable Unamortized Allowance Current Percentage
NotesReceivableUnamortizedAllowanceCurrentPercentage
1 pure
CY2024Q2 BLNC Notes Receivable Unamortized Allowance Current
NotesReceivableUnamortizedAllowanceCurrent
141000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2835 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11340 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
497165 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
491496 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
2385 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8504 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
497165 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
491496 usd

Files In Submission

Name View Source Status
0001493152-24-031278-index-headers.html Edgar Link pending
0001493152-24-031278-index.html Edgar Link pending
0001493152-24-031278.txt Edgar Link pending
0001493152-24-031278-xbrl.zip Edgar Link pending
blnc-20240630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blnc-20240630_cal.xml Edgar Link unprocessable
blnc-20240630_lab.xml Edgar Link unprocessable
blnc-20240630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blnc-20240630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed